Law360, New York (January 26, 2012, 4:29 PM ET) -- The Federal Circuit has granted Watson Pharmaceuticals Inc. and Amphastar Pharmaceuticals Inc. a stay of a preliminary injunction won by Momenta Pharmaceuticals Inc. that prevented them from marketing or selling a generic equivalent to blood-thinning medication Lovenox, Watson said Thursday.
Amphastar and Watson plan to launch a competing enoxaparin sodium injection product immediately, according to a statement from Watson.
Cambridge, Mass.-based Momenta and partner Novartis AG are currently the only companies that market a generic version of Sanofi SA's Lovenox in the U.S.
On Tuesday, attorneys...
Fed. Circ. Lifts Block On Generic Lovenox Sales
To view the full article, take a free trial now.
